Clinical trial
Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be…
NCT00467194 · National Cancer Centre, Singapore, Other · Completed
Key facts
| NCT number | NCT00467194 |
|---|---|
| Title | Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery |
| Official title | A Phase I Study of Rapamycin in Combination With Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma |
| Lead sponsor | National Cancer Centre, Singapore, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Drug |
| Interventions | Rapamycin, Bevacizumab |
| Enrollment | 27 |
| Start date | Dec 1, 2006 |
| Primary completion | May 1, 2011 |
| First posted | Apr 27, 2007 |
| Last update posted | Jun 17, 2013 |
| Countries | Singapore |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: